Rem On Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
REM-on neurons are sleep-state gating cells that increase firing at REM onset and remain active during rapid-eye-movement sleep epochs.[1][2] They are concentrated in pontine and medullary REM-generating networks, especially around the sublaterodorsal/mesopontine region, with downstream recruitment of medullary-spinal atonia pathways.[2:1][3] In clinical neurodegeneration, this circuit matters because REM instability and loss of REM atonia are early network-level abnormalities in synucleinopathies and can precede classic motor syndromes.[4][5]
| Taxonomy | ID | Name / Label |
|---|---|---|
| Allen Brain Cell Atlas | Search | REM-On Neurons |
| Cell Ontology (CL) | Search | Check classification |
| Human Cell Atlas | Search | Check expression data |
| CellxGene Census | Search | Check cell census |
REM-on ensembles include glutamatergic premotor cells in pontine REM generators and cholinergic contributors in mesopontine nuclei such as pedunculopontine nucleus neurons.[2:2][6] Their activity is coordinated against REM-suppressing monoaminergic populations (locus coeruleus and dorsal raphe), creating a reciprocal switch architecture rather than a single "REM center."[1:1][2:3]
Core organizational principles:
REM-on firing climbs abruptly at NREM-to-REM transitions and helps sustain REM episodes until counter-regulatory wake systems reactivate.[1:3][2:5] This gating is sensitive to cholinergic and glutamatergic tone, as well as circadian and homeostatic sleep pressure.
A key downstream function is suppression of spinal motor output during REM sleep. Failure of this pathway produces REM sleep without atonia and dream-enactment behaviors.[3:2][4:1]
REM-state circuitry interacts with hippocampal-limbic systems associated with emotional memory recalibration and salience updating.[7:1] These functions are relevant to neurodegeneration because sleep fragmentation can amplify daytime cognitive and affective symptoms.
Idiopathic REM sleep behavior disorder (iRBD) is one of the strongest prodromal markers for later Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.[4:2][5:1] From a circuit perspective, iRBD reflects early degeneration or dysregulation in REM-on/atonia networks before widespread nigrostriatal failure.
In established Parkinson's disease, REM-on network dysfunction contributes to nocturnal motor behaviors, fragmented sleep, daytime sleepiness, and interactions with mood/cognitive symptoms.[4:3][6:1] This makes REM circuitry a practical target for integrated non-motor management.
REM-on dysfunction is not exclusive to synucleinopathies; it can be perturbed in tauopathies and mixed neurodegenerative syndromes with brainstem involvement. The mechanistic utility is as a network biomarker of pontine-medullary vulnerability rather than a diagnosis-specific lesion.
Potential monitoring layers include:
Intervention strategies include melatonin/clonazepam for symptomatic RBD control and disease-modifying trials enriched using REM-on circuit phenotypes.[4:5] A key research challenge is distinguishing treatment effects on symptom expression versus underlying degeneration.
The study of Rem On Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Saper CB, Fuller PM, Pedersen NP, Lu J, Scammell TE. Sleep state switching. Neuron. 2010. ↩︎ ↩︎ ↩︎ ↩︎
Lu J, Sherman D, Devor M, Saper CB. A putative flip-flop switch for control of REM sleep. Nature. 2006. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Weber F, Hoang Do JP, Chung S, et al. Regulation of REM and non-REM sleep by periaqueductal GABAergic neurons. Nature. 2015. ↩︎ ↩︎ ↩︎
Iranzo A, Santamaria J, Tolosa E. The clinical and pathophysiological relevance of REM sleep behavior disorder in neurodegenerative disease. Sleep Medicine. 2013. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Postuma RB, Gagnon JF, Bertrand JA, et al. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology. 2015. ↩︎ ↩︎ ↩︎
Karachi C, Grabli D, Bernard FA, et al. Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. Brain. 2010. ↩︎ ↩︎
Peever J, Fuller PM. The biology of REM sleep. Current Biology. 2017. ↩︎ ↩︎